FCMI
RARX

Foresite Capital Management III’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Foresite Capital Management III’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50,000
Closed -$266K – 25
2018
Q1 		$266K Buy
+50,000
New +$357K 0.06% 24

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Foresite Capital Management III's RARX Position: Q2 2018 in Review

Foresite Capital Management III sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2018, closing a stake of 50,000 shares — an estimated $266K sold.

Foresite Capital Management III first reported a position in RARX in Q1 2018 and held it in 1 quarter. The position peaked at $266K in Q1 2018. 62 funds tracked by Wall St. Rank hold RARX as of Q2 2018.

  • Foresite Capital Management III reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Foresite Capital Management III sold 50,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2018, an estimated $266K.
  • Foresite Capital Management III first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • Foresite Capital Management III's Ra Pharmaceuticals, Inc. Common Stock position peaked at $266K in Q1 2018.
  • 62 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2018.

Based on Foresite Capital Management III's 13F filing for Q2 2018, filed 14 Aug 2018.